{"id":1676,"date":"2013-06-14T13:15:15","date_gmt":"2013-06-14T13:15:15","guid":{"rendered":"\/?p=1676"},"modified":"2013-06-14T13:15:18","modified_gmt":"2013-06-14T13:15:18","slug":"biomatrix-scientific-group-otcmktsbmsn-may-be-waking-up","status":"publish","type":"post","link":"\/articles\/biomatrix-scientific-group-otcmktsbmsn-may-be-waking-up\/","title":{"rendered":"BioMatrix Scientific Group (OTCMKTS:BMSN) May Be Waking Up"},"content":{"rendered":"

After a long and boring drift, BioMatrix Scientific Group (OTCMKTS:BMSN<\/a>) piked a bit more, adding 36$ to $0.0034. This is not too hard for such an underpriced ticker, and in weeks past BMSN<\/a> has had a few days of upward momentum and growing volumes, ending in sales soon. With the weekend looming, BMSN<\/a> is certainly still on shaky ground. \"BMSN0614.png\" <\/p>\n

A double-zero stock is usually supported by some form of promotional activity. BMSN<\/a> has not been mentioned for a month, since its last email on May 6th, where the graph shows a clear spike in buying volumes. But BMSN<\/a> boosted its publicity record with the recent acquisition of a patent, through its subsidiary Regen BioPharma Inc. \"STOA0614.png\"<\/p>\n

Also, BMSN<\/a> has been busy with the FDA, recently sending a response on the agency’s comments regarding drug HemaXellerate. Thus, BMSN<\/a> is going under a double dynamic, that of a pharma company attracting investors with a promise of future drug releases, as well as that of an underpriced stock, almost always attractive for a speculative bet.<\/p>\n

But the financial data show not a successful drug industry newcomer- rather, an unsuccessful company trying to boost its ticker price with promotions:<\/p>\n